3,7-二羟基雄甾烷-17-酮 | 21080-62-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 3,7-二羟基雄甾烷-17-酮
• 英文名称: 3α,7α-dihydroxy-5α-androstan-17-one
• 英文别名: 3alpha,5beta,7alpha-3,7-Dihydroxyandrostan-17-one；(3R,5R,7R,8R,9S,10S,13S,14S)-3,7-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
• CAS: 21080-62-6
• 化学式: C₁₉H₃₀O₃
• 分子量: 306.445
• InChiKey: VFPMCLQMAUVEHD-SOWWQRNPSA-N

物化性质

• 沸点：
  454.7±45.0 °C(Predicted)
• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,7-二羟基雄甾烷-17-酮 、 potassium tert-butylate 、 水 在 乙基三苯基溴化膦 氩 、 ice 、 水 、 crude material 、 silica gel 、 ethyl acetate n-hexane 作用下， 以 四氢呋喃 为溶剂， 反应 72.5h， 以to afford, on elution with ethyl acetate--hexane (2:1), 0.888 g of material (82%)的产率得到(Z)-(3α,5β,7α)-pregn-17(20)-ene-3,7-diol
  参考文献：
  名称：

  Process and intermediates for the synthesis of Vitamin D.sub.3

  摘要：

  本公开涉及一种从17-酮类固醇合成降甘胆酸、25-羟基胆固醇和1α，25-二羟基胆固醇的方法。通过将适当的17-酮类固醇与乙基三苯基膦卤化物反应，立体选择性地引入胆酸侧链，从而产生17-乙烯基衍生物，然后允许其与丙烯酸酯或丙炔酸酯反应，随后进行氢化。

  公开号：

  US04360470A1
• 作为产物：
  描述：

  雄酮 以 乙醇 为溶剂， 反应 72.0h， 以10%的产率得到3,7-二羟基雄甾烷-17-酮
  参考文献：
  名称：

  微生物转化。第4部分。秀丽线虫Cunninghamella elegans对5α-雄激素17-和17a-氮杂-D-homo-5α-雄激素17-的微生物转化

  摘要：

  秀丽隐杆线虫对5α-雄甾烷17-one，3β-乙酰氧基和3α-羟基衍生物的微生物转化主要由1β，7-二羟基化或7-单羟基化。3α-乙酰氧基-5α-雄烷-17-主要发生6β，11β-二羟基化。17a- Aza- D -homo-5α-androstan-17-one和3α-乙酰氧基衍生物在6β或7α处主要发生单羟基化反应，而3β-乙酰氧基衍生物虽然进行类似的单羟基化反应却得到良好的收率。 9α-单羟基化产物。

  DOI：

  10.1039/p19810001041

文献信息

• METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS
  申请人：Ge Yu

  公开号：US20120214987A1

  公开（公告）日：2012-08-23

  The invention relates to processes for preparing 3α-O-linked steroids including 3α-O-linked-androst-5-ene steroids and 3α-O-linked-5a-androstane steroids. In one process a 3α,4α-epoxy androst-5-en-17-one is predominately reduced at the epoxy moiety wherein reduction of the 3α,4α epoxy functional group occurs preferentially at position C4 with retention of configuration at position C3 to provide a 3α-O-linked-androst-5-ene steroid. In another process, conditions are provided for inversion of configuration of a 3β-hydroxy-androst-5-ene steroid by the Mitsunobu reaction to provide a 3α-O-linked-androst-5-ene steroid with reduced amounts of 3α,5α-cycloandrostane side-product impurities.

  该发明涉及制备3α-O-连接类固醇的过程，包括3α-O-连接-雄烯类固醇和3α-O-连接-5α-雄烷类固醇。在一个过程中，3α,4α-环氧基雄-5-烯-17-酮主要在环氧基团处还原，其中3α,4α-环氧官能团的还原优先发生在C4位置，并保留C3位置的构型，以提供3α-O-连接-雄烯类固醇。在另一个过程中，通过Mitsunobu反应提供条件，使3β-羟基雄-5-烯类固醇的构型发生倒置，以提供含有减少量3α,5α-环雄烷副产物杂质的3α-O-连接-雄烯类固醇。
• Immune modulation method using steroid compounds
  申请人：——

  公开号：US20030060425A1

  公开（公告）日：2003-03-27

  The invention provides compositions comprising formula 1 steroids, e.g., 16&agr;-bromo-3 &bgr;-hydroxy-5&agr;-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

  本发明提供了由式 1 类固醇（如 16&agr;-溴-3&bgr;-羟基-5&agr;-雄甾烷-17-酮半水合物）和一种或多种赋形剂组成的组合物，包括由含水量小于约 3% v/v 的液体制剂组成的组合物。这些组合物可用于制造改进的药物制剂。本发明还提供了类固醇化合物（如 16&agr;-溴-3&bgr;-羟基-5&agr;-雄甾烷-17-酮的类似物）的间歇给药方法和用于此类给药方案的组合物。本发明进一步提供了抑制病原体复制、改善与免疫失调相关的症状以及使用化合物调节受试者免疫反应的组合物和方法。本发明还提供了制造和使用这些免疫调节组合物和制剂的方法。
• Microbial Baeyer–Villiger oxidation of 5α-steroids using Beauveria bassiana. A stereochemical requirement for the 11α-hydroxylation and the lactonization pathway
  作者：Alina Świzdor、Anna Panek、Natalia Milecka-Tronina

  DOI：10.1016/j.steroids.2014.01.006

  日期：2014.4

  Beauveria bassiana KCH 1065, as was recently demonstrated, is unusual amongst fungal biocatalysts in that it converts C-19 3-oxo-4-ene and 3 beta-hydroxy-5-ene as well as 3 beta-hydroxy-5 alpha-saturated steroids to 11 alpha-hydroxy ring-D lactones. The Baeyer-Villiger monooxygenase (BVMO) of this strain is distinguished from other enzymes catalyzing BVO of steroidal ketones by the fact that it oxidizes solely substrates with 11 alpha-hydroxyl group. The current study using a series of 5 alpha-saturated steroids (androsterone, 3 alpha-androstanediol and androstanedione) has highlighted that a small change of the steroid structure can result in significant differences of the metabolic fate. It was found that the 3 alpha-stereochemistry of hydroxyl group restricted "normal" binding orientation of the substrate within 11 alpha-hydroxylase and, as a result, androsterone and 3 alpha-androstanediol were converted into a mixture of 7 beta-, 11 alpha- and 7 alpha-hydroxy derivatives. Hydroxylation of androstanedione occurred only at the 11 alpha-position, indicating that the 3-oxo group limits the alternative binding orientation of the substrate within the hydroxylase. Only androstanedione and 3 alpha-androstanediol were metabolized to hydroxylactones. The study uniquely demonstrated preference for oxidation of equatorial (11 alpha-, 7 beta-) hydroxyketones by BVMO from B. bassiana. The time course experiments suggested that the activity of 17 beta-HSD is a factor determining the amount of produced ring-D lactones. The obtained 11 alpha-hydroxylactones underwent further transformations (oxy-red reactions) at C-3. During conversion of androstanedione, a minor dehydrogenation pathway was observed with generation of 11 alpha,17 beta-dihydroxy-5 alpha-androst-1-en-3-one. The introduction of C1-C2 double bond has been recorded in B. bassiana for the first time. (C) 2014 Elsevier Inc. All rights reserved.
• [EN] METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS<br/>[FR] PROCÉDÉS ET COMPOSÉS UTILISÉS POUR PRÉPARER DES STÉROÏDES 3 ALPHA-OXYGÈNE SUBSTITUÉS
  申请人：HARBOR BIOSCIENCES INC

  公开号：WO2012083090A2

  公开（公告）日：2012-06-21

  The invention relates to processes for preparing 3α-O-linked steroids including 3α-O-linked-androst-5-ene steroids and 3α-O-linked-5α-androstane steroids. In one process a 3α,4α-epoxy androst-5-en-17-one is predominately reduced at the epoxy moiety wherein reduction of the 3α,4α epoxy functional group occurs preferentially at position C4 with retention of configuration at position C3 to provide a 3α-O-linked-androst-5-ene steroid. In another process, conditions are provided for inversion of configuration of a 3β-hydroxy-androst-5-ene steroid by the Mitsunobu reaction to provide a 3α-O-linked-androst-5-ene steroid with reduced amounts of 3α,5α-cycloandrostane side-product impurities.